The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.
|
|
|
|
|
Request for Information on Biomarkers for Prediction of Response to Obesity Therapies and Sustained Weight Loss - The purpose of this RFI is to solicit preliminary ideas, resource estimates, and timelines regarding the creation and progressive validation of approaches to predict long-term weight loss response from short-term controlled weight loss clinical trials in adults.
CLICK HERE FOR THE RFI >>
FNIH Biomarkers Consortium to Release Alzheimer’s Biomarker Data
CLICK HERE FOR THE RFP >>
Biomarkers Consortium pleased to announce Dr. Paul Deutsch, V-P, Sanofi, has been elected to fill the vacant seat on the BC's Executive Committee representing the pharmaceutical industry sector.
CLICK HERE FOR DR. DEUTSCH'S BIO >>
